Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $260,752.11 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 16,619 shares of the stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $15.69, for a total value of $260,752.11. Following the transaction, the insider now owns 206,750 shares in the company, valued at $3,243,907.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock opened at $15.79 on Monday. Centessa Pharmaceuticals plc has a 52 week low of $5.15 and a 52 week high of $17.59. The company has a quick ratio of 13.29, a current ratio of 13.29 and a debt-to-equity ratio of 0.27. The business has a 50 day moving average price of $13.01 and a 200-day moving average price of $10.84. The company has a market cap of $1.59 billion, a PE ratio of -11.12 and a beta of 1.44.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Jump Financial LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $114,000. Trexquant Investment LP bought a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at $114,000. Franklin Resources Inc. lifted its position in shares of Centessa Pharmaceuticals by 34.1% during the 4th quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company’s stock valued at $8,882,000 after buying an additional 283,469 shares during the last quarter. Platinum Investment Management Ltd. grew its stake in shares of Centessa Pharmaceuticals by 12.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 381,083 shares of the company’s stock worth $3,033,000 after acquiring an additional 43,539 shares during the period. Finally, Octagon Capital Advisors LP increased its holdings in Centessa Pharmaceuticals by 333.2% in the 4th quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock worth $16,398,000 after acquiring an additional 1,584,500 shares during the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CNTA has been the topic of several research analyst reports. B. Riley started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 target price on the stock. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Guggenheim upped their price target on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Jefferies Financial Group raised their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and a consensus price target of $25.17.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.